Differentiation induction, and especially monocytic differentiation, seems to be a part of the therapeutic response to several new targeted therapies that are considered for AML therapy (see Section 7), and for the IDH inhibitor enasidenib, such differentiation induction seems to be necessary for an enasidenib-associated increase in venetoclax sensitivity [220]. The gene discussed is IDH1; the disease is acute myeloid leukemia.